Stevia / LOHAS Stock Alert: GLG (TSX: GLG) (OTC: GLGLF) Announces Filing of GRAS Notification With FDA for Luo Han Guo (Monk Fruit) Extracts

Vancouver, B.C. - May 22, 2014 (Investorideas.com Newswire) GLG Life Tech Corporation (TSX: GLG) (OTC: GLGLF) ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high quality natural sweeteners, announces that it has submitted a Generally Recognized as Safe ("GRAS") notification with the United States Food and Drug Administration ("FDA") for its Luo Han Guo (Monk Fruit) extract products.

This notification represents many months of work developing the products and all required documentation for the FDA-administered GRAS process, in order to demonstrate that GLG's Luo Han Guo extracts meet the FDA's criteria for safety. This process included in-depth consultations with GRAS Associates, LLC, who convened an independent panel of scientists to spearhead the safety assessment. The GRAS notification covers three distinct Luo Han Guo extracts, MV30, MV 50, and MV60, each containing a minimum level of mogroside V (30%, 50%, and 60%, respectively).
GLG has set up a vertically integrated supply chain, including agriculture and processing, for Luo Han Guo in China. GLG differentiates itself from other Luo Han Guo producers in three ways: (1) its competitive advantage in establishing agriculture systems in China, including the introduction of Good Agriculture Practices (GAP) by its Luo Han Guo farmers, superior Luo Han Guo seedlings and its proven methods to expand the amount of farming in other crops such as stevia; (2) its advanced processing and extraction technology, which will enable GLG to more efficiently and economically produce Luo Han Guo extracts and (3) its large industrial processing capacity, which well positions GLG for anticipated growth in the Luo Han Market driven by international food and beverage companies. GLG is expecting its first fruit to be harvested at the end of the third quarter and to commence processing in late 2014. GLG is currently working with a number of international customers interested in its Luo Han Guo products and expects initial sales to be finalized prior to the start of production.
Additionally, GLG has GRAS projects underway for two high-purity stevia products, high-purity rebaudioside C and rebaudioside D; notifications for these are expected to be released for review by the FDA in 2014 as well. GLG already has the largest number of stevia products certified under the GRAS process, including rebaudioside A products ranging from purities of 50 to 97%, high-purity stevioside (STV) and high-purity rebaudioside M. GLG is committed to ensuring that each of its naturally-sourced sweetener products is fully documented as compliant with the FDA GRAS process.
About GLG Life Tech Corporation
GLG Life Tech Corporation is a global leader in the supply of high purity stevia extracts, an all-natural zero-calorie sweetener used in food and beverages. The Company's vertically integrated operations cover each step in the stevia supply chain including non-GMO stevia seed breeding, natural propagation, stevia leaf growth and harvest, proprietary extraction and refining, marketing and distribution of finished product. For further information, please visit www.glglifetech.com.
Forward-looking statements: This press release contains certain information that may constitute "forward-looking statements" and "forward looking information" (collectively, "forward-looking statements") within the meaning of applicable securities laws. Such forward-looking statements include, without limitation, statements evaluating the market, potential demand for stevia and general economic conditions and discussing future-oriented costs and expenditures. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or words and phrases that state or indicate that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
While the Company has based these forward-looking statements on its current expectations about future events, the statements are not guarantees of the Company's future performance and are subject to risks, uncertainties, assumptions and other factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such factors include amongst others the effects of general economic conditions, consumer demand for our products and new orders from our customers and distributors, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations, industry supply levels, competitive pricing pressures and misjudgments in the course of preparing forward-looking statements. Specific reference is made to the risks set forth under the heading "Risk Factors" in the Company's Annual Information Form for the financial year ended December 31, 2012. In light of these factors, the forward-looking events discussed in this press release might not occur.
Further, although the Company has attempted to identify factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
As there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements, readers should not place undue reliance on forward-looking statements.
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers Disclosure: GLG Life Tech Corporation (TSX: GLG) April 9th 2014 - two months news and content publication , two thousand five hundred per month. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Breaking Tech News: NXT-ID's (OTCQB: NXTD) Smart Wallet, Wocket™, Included in Aite Group New Report: Money Goes Mobile

SHELTON, Conn. - May 22, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, reports the company's next generation smart wallet, Wocket™, was recently featured in the Aite Group New Research Report: Money Goes Mobile.

Aite Group issued a press release on the Money Goes Mobile report on May 19th. NXT-ID, Inc. has announced advance ordering for the Wocket smart wallet commences on May 28th, at 5:00 p.m. EDT.
Excerpt from Aite Report:
Founded in 2012
HQ in Shelton, Connecticut
On May 28, 2014, NXT-ID plans to launch its smart wallet offering, Wocket, at a press conference, after which it plans to accept pre-orders. The Wocket is a smart card that allows consumers to load up to 10,000 credit cards, debit cards, loyalty cards, gift cards, as well as many other types of cards in aggregate.
NXT-ID's focus appears to be on security, and it states the Wocket will be biometrically secure and accessible only through a combination of voice, PIN, or pattern sequences and that the smart card will be zeroed out after each transaction, making it useless to another if lost or stolen.
The Wocket will be available for US$149
The full report is available at: http://www.aitegroup.com/report/money-goes-mobile
According to the Aite Group in its report, "Money Goes Mobile" tracks the evolution of the digital wallet ecosystem, the mobile wallet's growing pains, and the success stories emerging as an industry ripe for change brings together the leaders that can create and deliver robust mobile wallet products.
Aite Group also breaks down the different types of digital wallet services that exist today, identifies the barriers for adoption, and examines the value propositions of the various technologies for the consumers, merchants, and payment providers.
The research is based on more than 20 interviews with executives and product managers within the financial technology industry from February to April 2014.
Aite Group's analysis indicates that technology companies and mobile payment providers should ensure that the user experience and loyalty or reward programs are paramount in their products in order to incentivize consumers to abandon traditional payment instruments and adopt mobile money.
Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.
Advance ordering will be available May 28th at http://www.wocketwallet.com/
The full Wocket product FAQ is available to consumers and media at http://nxt-id.com/wocket-faq/
Interested consumers can also sign up for product info and news alerts in anticipation of the product. http://www.wocketwallet.com/
About Aite Group
Aite Group partners with participants in the international financial services marketplace, leveraging our analysts' industry experience to challenge, to advice, and to catalyze growth through independent market research and timely consulting. Attuned to the needs and strengths of our clients, Aite Group builds bridges, brokers insight, and offers actionable advice that companies rely on to build their relationships and grow their businesses. http://www.aitegroup.com
Press release : http://www.aitegroup.com/what-customers-want%E2%80%94besides-money%E2%80%94-their-mobile-wallets
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013: Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous service. More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients

SAN DIEGO - May 21, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier® therapy.

The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of viral pathogens and tumor-secreted exosomes from the entire circulatory system to improve the benefit of drug therapies administered to infectious disease and cancer patients. In HCV care, the device is positioned to address drug resistance associated with emerging all-antiviral therapies and also targets to accelerate HCV RNA depletion at the outset of peginterferon+ribavirin (PR) therapy.
Aethlon recently disclosed that the United States Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) that now allows the Company to initiate HCV human feasibility studies of Hemopurifier® therapy in the United States. Aethlon announced yesterday that its first U.S. clinical study will be conducted at the DaVita MedCenter Dialysis in Houston, Texas. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
In the reported study, HCV-infected individuals were enrolled to receive three six-hour Hemopurifier® treatments during the first three days of a 48-week peginterferon+ribavirin (PR) treatment regimen. The study was conducted under the leadership of Dr. Vijay Kher at the Medanta Medicity, a multi-specialty medical institute established to be a premier center for medical tourism in India. Aethlon reported that Hemopurifier® therapy was well tolerated and without device-related adverse events in twelve treated patients. Of these twelve patients, nine completed the Hemopurifier-PR treatment protocol, including seven genotype-1 patients and two genotype-3 patients. Seven of the nine patients (n=7/9) achieved a sustained virologic response (SVR), which is the clinical definition of treatment cure and is defined as undetectable HCV RNA 24-weeks after the completion of the 48-week PR drug regimen. Both genotype-3 patients achieved a SVR (n=2/2), while five of the seven genotype-1 patients achieved a SVR (n=5/7).
Of the nine patients that completed the protocol, five (n=5/9) also achieved a rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts SVR cure rates. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients will achieve a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients.
Data from three patients were not included in the reported dataset. Among the three patients was a genotype-5 patient who discontinued PR therapy at day 180, yet remained undetectable at 1.5 years after initiation of therapy. The second was a genotype-3 patient who was unable to tolerate PR therapy and, as a result, discontinued PR therapy at day-90, yet was still undetectable one year after initiating therapy. The third patient, who had the genotype-1 virus, was reported undetectable at the completion of the 48-week PR treatment regimen, but SVR results are not due on that patient until September of this year.
"It appears the intermittent application of Hemopurifier® therapy during just the first three days of a 48-week interferon regimen can significantly influence treatment outcomes," stated Aethlon Chairman and CEO, Jim Joyce. "We now look forward to the clinical advancement of Hemopurifier® protocols against infectious viral pathogens and cancer indications in the United States."
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

NXT-ID's (OTCQB: NXTD) News: Wocket™ Smart Wallet to be Demonstrated at Event May 28th at Plaza in New York City

SHELTON, Conn. - May 21, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market announces Gino Pereira, CEO of NXT-ID, Inc., will demonstrate the functionality of its next generation smart wallet, Wocket™, designed to replace all the cards in your wallet, at the May 28th launch event at the Plaza in New York City.

The company also releases new product images and videos for the Wocket™ and the Wocket™ card at www.wocketwallet.com
Gino Pereira, CEO of NXT-ID, Inc. said, "Wocket™, is a device that contains a single card that is used to make financial transactions and to process information. A user scans their cards directly into wocket with a scanner that we provide. When processing a transaction, the user accesses the touch screen on wocket after first identifying himself or herself through voice authentication or using a PIN. After that it's as simple as pressing the desired button on the touch screen to use the wocketcard, which now has the information from your card of choice. We take a big bulky wallet and turn it into a sleek, secure and simple solution."
"Wocket is very unique in the payment space, different from a mobile wallet, mobile payment app or other multi card consolidators. Wocket is separate from your phone, so you never have to worry about having all that information in the wrong hands, or running out of battery life. We don't just replace your credit cards; we can store up to 10,000 cards – your loyalty cards, coupons, identity cards, basically any card in your wallet. They key is that wocket also stores your cash so it is a complete replacement for your wallet. "
He went on to state, "We are extremely excited to introduce Wocket to the multitude of consumers that are concerned about the safety of their identity and payment. Wocket is a convenient and safer alternative to a traditional wallet."
Media and shareholders wishing to attend the May 28th event can email info@nxt-id.comor call 800 -665-0411 (Limited attendance so registration is required in advance)
Wocket™ Consumer FAQ Hi- lights:
"What is Wocket ™?
Wocket™ is a smart wallet. Like the smart phone and smart watch, NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.
"What does Wocket™ do?
Wocket™ locks all of your private information in an electronic "vault", where only an authenticated owner can authorize access to the data. Thus, you can "lock it with Wocket™ in your pocket", protecting your private information from unauthorized access.
"What makes Wocket™ smart?
Wocket™ smart wallet protects all of your private information inside an electronic vault while reducing the number of cards in your wallet. Dynamic pairing for authentication and encrypted data transfer with other secondary devices along with a plethora of new, innovative features makes Wocket™ the smartest wallet ever devised.
"How is Wocket™ different from other smart card solutions?
Wocket™ is not a smart card - it is a smart wallet. Thus, it can communicate with smart cards, but is not limited in the number, type, or method of communication of private information that typically restricts the use of a smart card. Furthermore, Wocket™ is not dependent on proximity or any other external factors to secure and choose soft-cards containing private information.
"How is Wocket™ different from other digital wallet solutions?
Rather than replace a wallet as many "digital wallet" technologies attempt to do, we chose to improve the wallet. Unlike other digital wallet solutions that depend on connectivity to choose a payment account, Wocket™ does not depend upon the cloud to select or make a payment.
"Does Wocket™ require another device, such as a cell phone?
No. Although Wocket™ does not require any other peripheral for security or "proximity sensing", Wocket™ can authenticate with secondary devices prior to transaction as an additional step in security as well as utilize a Wocket™ app on other devices to select or manage a soft-card, all without revealing private information.
"How do I access my private information?
A combination of biometrics, personal PIN or pattern provides multi-factor security for your Wocket™. Once Wocket™ verifies your identity, you can simply select whatever soft-card or information you want from the touch screen display, or in some configurations, your voice command.
"How many cards can be securely stored on a Wocket™?
Up to 10,000 cards, records, coupons, etc. and up to 100 voice commands can also be stored on Wocket™. More can be supported with optional additional memory.
The full Wocket product FAQ is available to consumers and media at http://nxt-id.com/wocket-faq/
Product videos can be seen at http://www.wocketwallet.com/
To advance order the Wocket or sign up for news and updates please visit http://www.wocketwallet.com/
The Wocket will retail for $149.99.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013: Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous service. More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Q&A: Award Winning Movie Producer and Businessman Chad A. Verdi Discusses Hollywood Deals and Tech Investments in Apple and NXT-ID Inc.'s (OTCQB: NXTD) Wocket

NEW YORK and POINT ROBERTS, Washington - May 19, 2014 (Investorideas.com Newswire)
Verdi to Produce/Executive Produce Three Films with Oscar winning Director Martin Scorsese: Star studded actors include Liam Neeson, Andrew Garfield, Miles Teller, Aaron Eckhart and Adam Driver
"You may see a Wocket in a very famous Pocket" - C. Verdi

Investorideas.com, a global news source covering leading topics and sectors including technology and entertainment, releases an exclusive Q&A with entrepreneurial movie producer, businessman and investor Chad A. Verdi of Rhode Island.
Mr. Verdi discusses new and recent ventures including new movie deals and his investments in game-changing technologies, including Apple and biometric mobile security company NXT-ID Inc., (OTCQB: NXTD), which is currently preparing to launch its smart wallet, the Wocket™ (www.wocketwallet.com), with advance orders starting May 28th.
Mr. Verdi notes, "I am always looking ahead and I'm never satisfied with 'good enough', My goal is to partner with the best, hire the best talent and invest in leading edge companies. Steve Jobs made Apple known for 'Think different', Richard Branson made his motto, 'Screw it , let's do it' and I live by 'Go big or go home'."
Q&A Interview:
Q: Investorideas.com
This past year has already seen you reach some key milestones; making movies with the best in Hollywood, like Martin Scorsese and your investment in NXTD is up over 300 percent in less than a year. What are you most excited about for the balance of this year?
A: Chad A. Verdi
Well, that's a tough one. I guess I am the most excited about NXTD right now, only because they are about to launch the Wocket™ this month. Wocket™ is a smart wallet with a re-programmable single credit card device that operates under a secured system using biometrics.
I feel it will change the way people make credit card payments worldwide. Everyone is trying to get in on this game with mobile payments, mobile wallets, mobile apps like LOOP and COIN. Everyone is trying to figure out the best way to do it. I think Wocket™ has the right approach; separate from your phone. Most people are concerned about what happens if they lose their phone or it gets stolen - what happens with all that payment info on your phone? With Wocket™, it's not a worry because after each transaction it basically goes back to a blank card. Your identity and payment info are safe!
It's great to think I originally invested in this a few years ago and now it may become the leader in the payment sector that I thought it would!
Q: Investorideas.com
In terms of your investments, you invest in both large companies like Apple and Yahoo and other big tech and entertainment companies but you also take risks and invest in smaller companies with emerging technology like NXTD (OTCQB: NXTD). Where do you see the biggest potential pay-off?
A: Chad A. Verdi
I obviously wish I would have had the opportunity to get into Apple from the beginning. I would have bet big on it, just like I have with NXTD (OTCQB: NXTD). Companies that take a different path from what the competition is doing represent the biggest opportunity, if it works.
Steve Jobs set the course for Apple, I still love the company but it's hard to know if the vision will stay intact. NXTD is still young and they are taking a revolutionary approach to payments and identity issues, very different from their competitors and I like that.
In my opinion, I see a big risk/reward opportunity here today because they have a product that every consumer will want and currently needs. The Wocket™ can store over 10,000 credit cards/coupons, under a secured system. It's never been done before. If they are successful in delivering this product; the sky is the limit. They could be the next Apple and that is my second-largest holding.
Q: Investorideas.com
The company stated that they will launch the Wocket™ May 28th at the Plaza Hotel in New York and will be taking advance orders for the Wocket™ once the event is done. Will you be attending and will you be buying one once advance orders are opened up?
A: Chad A. Verdi
For sure I will be there supporting them and seeing first-hand how the Wocket™ is embraced. And of course, I will be buying many, many Wockets™! I will be giving them out to all of my actor and celebrity friends in Hollywood. Soon, you may see a Wocket™ in a very famous pocket! I also love the fact that the company is promoting the Wocket like Apple does with the launch of each IPhone - it's an event. They're running commercials on CNBC news along with using the Plaza hotel for the launch. They are also bringing in Miss Universe as a celebrity guest; it a first-class event.
Q: Investorideas.com
Speaking about Hollywood and movies, you and your wife Michelle are now involved in three projects with Oscar-winning director Martin Scorsese and some of the biggest names in Hollywood. According to IMDB you have signed on Liam Neeson, Andrew Garfield, Miles Teller, Aaron Eckhart and Adam Driver. On top of this, I read that you have signed a 10 picture deal with Screen Media films. It seems like you are on fire! How did this all come about?
A: Chad A. Verdi
Yes, it's just nuts, crazy nuts! It all started when Mr. Scorsese and his producing partner Emma Koskoff agreed to join my passion project,' Bleed for This'. My wife Michelle and I met with them a few times in New York and they invited us to the premiere of 'The Wolf of Wall Street'. Then I was asked to get involved with a film called 'Bad Hurt' that was filmed in New York. Soon after that, things just escalated to where Michelle and I agreed to join Marty and Emma in his passion project called 'Silence'. The other two movies include 'The New York Review of Books: A 50 Year Argument' and then we'll produce my passion project, 'Bleed For This', the true-life story of five-time world champion, Rhode Island boxer, Vinny Pazienza.
Q: Investorideas.com
That is exciting and all happening very fast. How many years will it take you to complete these four films and what about the ten picture deal with Screen Media?
A: Chad A. Verdi
That's what's amazing. Eighteen months in regards to the four films: Bad Hurt is in post-production right now along with A 50 Year Argument. Bleed for This and Silence will be filmed this fall with completion dates no later than fall 2015, just in time for the Oscars. As far as the 10 picture deal with Screen Media Films, we are currently filming the first film called 'Almost Mercy' now and expect to release that film in December 2014. Then we begin filming the 2nd film in early 2015. The goal is to meet our obligations on the 10 picture deal prior to 1/1/2018. We are able to facilitate this because we have two production companies, The Woodhaven Production Company and Verdi Productions. Both companies are working separately and independent of one another and this gives us the capacity to handle the volume of projects we are involved with.
About the Verdi Productions and Woodhaven Production Company:
Both Verdi Productions and The Woodhaven Production Company are fully funded film production companies, covering all aspects of filmmaking from conception of script through postproduction. http://www.woodhavenfilms.com/, http://www.verdifilms.com/
About Chad Verdi
Chad A. Verdi, CEO: Chad A. Verdi is a producer and actor, known for Loosies (2011), Inkubus (2011) and Infected (2012). Full Bio: http://www.imdb.com/name/nm3838148/
Michelle L. Verdi Music and Talent Supervisor Media
Bio: http://www.imdb.com/name/nm4090091
About InvestorIdeas.com:
InvestorIdeas.com is a global news source covering leading sectors including biotech stocks tech and mobile stocks, mining, energy, waters stocks, renewable energy stocks, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: Investorideas is currently compensated by NXTD: five thousand per month plus 144 shares from a previous agreement. Disclosure: Chad a Verdi is long NXTD share in NXTD
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
+1-800-665-0411 - Source http://www.Investorideas.com
SOURCE Investor Ideas

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Definitive Agreement with DaVita Clinical Research and Site Location and Principal Investigator of Hepatitis C Virus (HCV) Clinical Study

SAN DIEGO - May 20, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon further announced that the Principal Investigator for this study will be Dr. Stephen Z. Fadem.

The clinical trial site location will be DaVita MedCenter Dialysis in Houston. Dr. Fadem is co-medical director of DaVita MedCenter Dialysis and this center is one of the three largest dialysis centers in the country with 72 treatment stations.
Aethlon previously disclosed that the United States Food and Drug Administration (FDA) had approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier in the United States. Under the feasibility study protocol, Aethlon is to treat ten ESRD patients infected with Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease indications.
"The combination of DCR, DaVita MedCenter Dialysis, and Dr. Fadem provides Aethlon with the ideal team of professionals and infrastructure with which to conduct our infectious disease clinical study. Additionally, their proximity to M.D. Anderson Cancer Center and other specialty facilities located within the Texas Medical Center provide for a unique location to conduct future clinical investigations of Hemopurifier® therapy in a variety of life-threatening health conditions," stated Aethlon Medical CEO Jim Joyce.
DCR is a specialty contract research organization (CRO) with experience in conducting more than 300 early phase clinical trials. As a subsidiary of DaVita Healthcare Partners Inc, DCR has access to one third of the total U.S. ESRD patient population and maintains a network that exceeds 150 investigative physicians' practices at more than 250 clinical sites.
Dr. Fadem is a practicing Houston nephrologist and is currently the Chief Medical Officer at Kidney Associates, PLLC and the Medical Director for the Houston Kidney Center Integrated Service Network at DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine at Baylor College of Medicine.
He is a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology, diplomat of the American Board of Quality Assurance and Utilization Review Physicians (CHCQM - Certified Health Care Quality Management), and a member of the International Society of Nephrology, Renal Physicians Association, the American Association of Kidney Patients and The National Kidney Foundation. He is active in quality management, credentialing and peer review for his dialysis centers.
On a national level, he is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients, and a past vice-president of the Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD (end stage renal disease) Networks and was a member of the CMS Clinical Performance Measures Committee. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, computer technology and computer security. Dr. Fadem is a co-editor of AAKP Renalife and is a reviewer for several peer reviewed journals.
Dr. Fadem has been nationally recognized by receiving the American Association of Kidney Patient's Nova Award, the National Kidney Foundation's Distinguished Service Award. He has also received the National Kidney Foundation's Presidents Award and the Myron L. Jenkins Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He is the 2013 winner of the DaVita Core Value Award for Continuous Improvement. He has been named as one of America's Top Doctors by Castle Connolly and US News and World Report, and is consistently ranked as a Top Doctor in Houston by Texas Magazine.
About DaVita Kidney Care
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of March 31, 2014, DaVita Kidney Care operated or provided administrative services at 2,098 outpatient dialysis centers located in the United States serving approximately 165,000 patients. The company also operated 75 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company's leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit DaVita.com.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

See the CNBC Ad for NXT-ID's (OTCQB:NXTD) Next Generation Smart Wallet, Wocket™, Now on Youtube.com

SHELTON, CT - May 16, 2014 (Investorideas.com Newswire) NXT-ID, Inc. (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, is pleased to release to consumers and shareholders the first series of 30 second spots on CNBC for its next generation smart wallet, Wocket™.

The commercial is available to view on the company home page at http://www.nxt-id.com/ and on youtube.com at http://www.youtube.com/watch?v=8kJid_JAbhg
Wocket™ is a smart wallet in the same vein as the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.
The consumer get to know Wocket™ campaign is in advance of the previously announced May 28 th press conference and marketing event to be held at the Plaza Hotel in New York City.
Media and shareholders wishing to attend the May 28 th event can email info@nxt-id.com
Advance orders will be available following the May 28 th event at 5:00 PM EST at http://www.wocketwallet.com/
Wocket Consumer FAQ:

"What is Wocket ™?

Wocket™ is a smart wallet. Like the smart phone and smart watch, NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices.
"What does Wocket™ do?
Wocket™ locks all of your private information in an electronic "vault", where only an authenticated owner can authorize access to the data. Thus, you can "lock it with Wocket™ in your pocket", protecting your private information from unauthorized access.
"What makes Wocket™ smart?
Wocket™ smart wallet protects all of your private information inside an electronic vault while reducing the number of cards in your wallet. Dynamic pairing for authentication and encrypted data transfer with other secondary devices along with a plethora of new, innovative features makes Wocket™ the smartest wallet ever devised.
"How is Wocket™ different from other smart card solutions?
Wocket™ is not a smart card - it is a smart wallet. Thus, it can communicate with smart cards, but is not limited in the number, type, or method of communication of private information that typically restricts the use of a smart card. Furthermore, Wocket™ is not dependent on proximity or any other external factors to secure and choose soft-cards containing private information.
"How is Wocket™ different from other digital wallet solutions?
Rather than replace a wallet as many "digital wallet" technologies attempt to do, we chose to improve the wallet. Unlike other digital wallet solutions that depend on connectivity to choose a payment account, Wocket™ does not depend upon the cloud to select or make a payment.
"Does Wocket™ require another device, such as a cell phone?
No. Although Wocket™ does not require any other peripheral for security or "proximity sensing", Wocket™ can authenticate with secondary devices prior to transaction as an additional step in security as well as utilize a Wocket™ app on other devices to select or manage a soft-card, all without revealing private information.
"How do I access my private information?
A combination of biometrics, personal PIN or pattern provides multi-factor security for your Wocket™. Once Wocket™ verifies your identity, you can simply select whatever soft-card or information you want from the touch screen display, or in some configurations, your voice command.
"How many cards can be securely stored on a Wocket™?
Up to 10,000 cards, records, coupons, etc. and up to 100 voice commands can also be stored on Wocket™. More can be supported with optional additional memory.
The full Wocket product FAQ is available to consumers and media at
http://nxt-id.com/wocket-faq/
Advance orders will be available following the May 28 th event at 5:00 PM EST at http://www.wocketwallet.com/

About NXT- ID Inc. -Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/, http://www.wocketwallet.com/
NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013: Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous service. More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.